PH17137A - Di-or trisubstituted xanthines with neuroleptic properties and pharmaceutical compositions containing them - Google Patents

Di-or trisubstituted xanthines with neuroleptic properties and pharmaceutical compositions containing them

Info

Publication number
PH17137A
PH17137A PH25561A PH25561A PH17137A PH 17137 A PH17137 A PH 17137A PH 25561 A PH25561 A PH 25561A PH 25561 A PH25561 A PH 25561A PH 17137 A PH17137 A PH 17137A
Authority
PH
Philippines
Prior art keywords
pharmaceutical compositions
compositions containing
neuroleptic properties
trisubstituted xanthines
xanthines
Prior art date
Application number
PH25561A
Other languages
English (en)
Inventor
Philippossian Georges
Enslen Marc
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of PH17137A publication Critical patent/PH17137A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH25561A 1980-05-02 1981-04-27 Di-or trisubstituted xanthines with neuroleptic properties and pharmaceutical compositions containing them PH17137A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH343180A CH643260A5 (fr) 1980-05-02 1980-05-02 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.

Publications (1)

Publication Number Publication Date
PH17137A true PH17137A (en) 1984-06-04

Family

ID=4255824

Family Applications (2)

Application Number Title Priority Date Filing Date
PH25561A PH17137A (en) 1980-05-02 1981-04-27 Di-or trisubstituted xanthines with neuroleptic properties and pharmaceutical compositions containing them
PH27345A PH17660A (en) 1980-05-02 1982-05-25 Di-or trisubstituted xanthines with neuroleptic properties;methods for their preparation and pharmaceutical compositons containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH27345A PH17660A (en) 1980-05-02 1982-05-25 Di-or trisubstituted xanthines with neuroleptic properties;methods for their preparation and pharmaceutical compositons containing them

Country Status (21)

Country Link
US (2) US4469698A (cs)
EP (1) EP0039780B1 (cs)
JP (1) JPS56169690A (cs)
AU (1) AU539258B2 (cs)
CA (1) CA1155841A (cs)
CH (1) CH643260A5 (cs)
CS (1) CS221829B2 (cs)
DD (1) DD158776A5 (cs)
DE (1) DE3169784D1 (cs)
DK (1) DK149856C (cs)
ES (1) ES502414A0 (cs)
FI (1) FI68831C (cs)
GB (1) GB2075505B (cs)
HK (1) HK49985A (cs)
HU (1) HU185256B (cs)
IL (1) IL62641A (cs)
MX (1) MX5974E (cs)
MY (1) MY8500517A (cs)
PH (2) PH17137A (cs)
PL (1) PL135383B1 (cs)
SG (1) SG20884G (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
EP0407651A3 (en) * 1989-07-10 1991-08-07 J. Uriach & Cia. S.A. Use of 1,3-diisobutyl-8-methylxanthine as a bronchodilator and antiallergy agent
EP0686157A1 (en) * 1993-02-26 1995-12-13 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
EP0799040B1 (en) * 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
WO1996018399A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
FR2741455B1 (fr) * 1995-11-21 1997-12-26 Alcatel Optronics Procede de formation d'une nappe de fibres optiques inclinees a dioptres de couplage
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
US9221821B2 (en) * 2012-06-05 2015-12-29 Forest Laboratories Holdings, Limited Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB701242A (en) * 1950-11-28 1953-12-23 Searle & Co Improvements in or relating to disubstituted 6-amino-1,2,3,4-tetrahydro-2,4-pyrimidinediones and methods of preparing the same
US2673848A (en) * 1951-12-29 1954-03-30 Searle & Co 3-alkenylxanthines and their lower 1-alkyl derivatives
GB759174A (en) * 1952-11-07 1956-10-17 Geigy Ag J R Improvements in diuretic acting xanthine derivatives
GB766754A (en) * 1954-01-27 1957-01-23 Geigy Ag J R New derivatives of 1.3-disubstituted and 1.3.8-trisubstituted xanthines and processes for their production
DE1091570B (de) * 1958-10-23 1960-10-27 Albert Ag Chem Werke Verfahren zur Herstellung von in 8-Stellung substituierten 1, 3-Dialkylxanthinen
GB982079A (en) * 1962-05-01 1965-02-03 Dresden Arzneimittel Process for the production of xanthine derivatives
US3740433A (en) * 1971-10-01 1973-06-19 Squibb & Sons Inc Anti-anxiety composition and method of use
CA1077932A (en) * 1976-03-31 1980-05-20 Berlex Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
CH654008A5 (fr) * 1979-05-22 1986-01-31 Nestle Sa Procede de preparation de 1,3,7-trialkylxanthines.

Also Published As

Publication number Publication date
GB2075505A (en) 1981-11-18
CH643260A5 (fr) 1984-05-30
DD158776A5 (de) 1983-02-02
US4469698A (en) 1984-09-04
FI68831C (fi) 1985-11-11
MX5974E (es) 1984-09-11
AU539258B2 (en) 1984-09-20
CS221829B2 (en) 1983-04-29
DK158481A (da) 1981-11-03
AU6961781A (en) 1981-11-05
HU185256B (en) 1984-12-28
IL62641A (en) 1985-01-31
DE3169784D1 (en) 1985-05-15
PL230936A1 (cs) 1982-06-07
EP0039780B1 (fr) 1985-04-10
PH17660A (en) 1984-10-25
ES8207532A1 (es) 1982-10-01
CA1155841A (en) 1983-10-25
PL135383B1 (en) 1985-10-31
US4581451A (en) 1986-04-08
HK49985A (en) 1985-07-05
JPS56169690A (en) 1981-12-26
FI811067L (fi) 1981-11-03
DK149856B (da) 1986-10-13
ES502414A0 (es) 1982-10-01
DK149856C (da) 1987-05-25
GB2075505B (en) 1984-01-11
EP0039780A1 (fr) 1981-11-18
FI68831B (fi) 1985-07-31
SG20884G (en) 1985-01-04
IL62641A0 (en) 1981-06-29
MY8500517A (en) 1985-12-31

Similar Documents

Publication Publication Date Title
DE3372705D1 (en) Pharmaceutical composition and its use
PH24267A (en) Androstane carbothioates and pharmaceutical compositions containing the same
PH17137A (en) Di-or trisubstituted xanthines with neuroleptic properties and pharmaceutical compositions containing them
ZA813465B (en) Pharmaceutical composition
DE3168067D1 (en) 2-guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them
JPS55119023A (en) Can and follower structure
JPS55111478A (en) Nn*heterocyclyl**methylacetoanilides and composition containing them
IL64054A0 (en) Imidazolylpyridines and pharmaceutical compositions containing them
DE3372983D1 (en) Radiation-sensible coating composition and its use
IL60376A (en) 3-diphenylmethyleneazetidines and pharmaceutical compositions containing them
PH18532A (en) Novel carbostyril derivatives and pharmaceutical compositions containing the same
DE3067811D1 (en) Ammelinium beta-octamolybdate and composition containing same
IL59177A0 (en) Spiro-quinolylhydantoins and pharmaceutical compositions containing them
IL70379A (en) Spiro-oxazolidones,-thiazolidones and-imidazolidones and pharmaceutical compositions containing them
ZA803098B (en) Didodecylammonium beta-octamolybdate and composition containing same
JPS5639067A (en) Pyrrolidineedione derivatives and mildewcidal composition containing them
DE3176849D1 (en) Pharmaceutical composition comprising 4-carbamoyl-imidazolium-5-olate
IL57882A0 (en) 2-thiophenecarboxamido-alkylmercaptans and pharmaceutical compositions containing them
IL68668A0 (en) Piperidinoquinazolines and pharmaceutical compositions containing them
IL62146A (en) Guanylamidines and pharmaceutical compositions containing them
PH22810A (en) Phenantrene derivatives and pharmaceutical compositions containing them
ZA803099B (en) Tripentylammonium decamolybdate and composition containing same
PH16800A (en) Pharmaceutical compositions containing dihydroergotamine and heparin
JPS5767596A (en) N-trifluoroacetyladriamycin-14-o-hemiglutarate and adipate and pharmaceutical composition containing same
JPS55134049A (en) Pressureereducing tin and its preparation

Legal Events

Date Code Title Description
AT Record of annual fee payments

Year of fee payment: 10